Mereo BioPharma Group plc (NASDAQ: MREO) announced its financial results for the year ended December 31, 2025, revealing a net loss of $41.9 million, a slight improvement from the $43.3 million loss in 2024. The company reported total cash and cash equivalents of $41.0 million as of December 31, 2025, which is expected to fund operations into mid-2027. The decrease in net loss was attributed to a reduction in research and development expenses, particularly for alvelestat and etigilimab, which fell by $3.2 million to $17.8 million. Mereo continues to focus on its three rare disease product candidates: setrusumab for osteogenesis imperfecta, alvelestat for alpha-1 antitrypsin deficiency-associated lung disease, and vantictumab for autosomal dominant osteopetrosis type 2. The company is actively engaged in discussions with potential partners for the Phase 3 development of alvelestat and plans to initiate a Phase 2 trial for vantictumab in the second half of 2026. Despite challenges in achieving statistical significance in primary endpoints for setrusumab, the company remains optimistic about its ongoing analyses and potential regulatory engagements. Mereo's leadership emphasized the importance of these developments in addressing unmet medical needs in rare diseases.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.